ERLN
gene geneOn this page
Also known as ELN
Summary
ERLN (endoregulin, HGNC:40032) is a protein-coding gene on chromosome 17q25.1, encoding Endoregulin (P0DI80). Inhibits the activity of the calcium ATPases ATP2A2/SERCA2 and ATP2A3/SERCA3 by decreasing their apparent affinity for Ca(2+).
Predicted to act upstream of or within negative regulation of ATPase-coupled calcium transmembrane transporter activity. Predicted to be located in endoplasmic reticulum membrane.
Source: NCBI Gene 100130933 — RefSeq curated summary.
At a glance
- Clinical variants (ClinVar): 6 total
- MANE Select transcript:
NM_001162997
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:40032 |
| Approved symbol | ERLN |
| Name | endoregulin |
| Location | 17q25.1 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | ELN |
| Ensembl gene | ENSG00000259120 |
| Ensembl biotype | protein_coding |
| OMIM | 620531 |
| Entrez | 100130933 |
Gene structure
Transcript identifiers
Ensembl transcripts: 3 — 3 protein_coding
ENST00000556126, ENST00000579469, ENST00000911162
RefSeq mRNA: 1 — MANE Select: NM_001162997
NM_001162997
CCDS: CCDS54166
Canonical transcript exons
ENST00000579469 — 2 exons
| Exon | Start | End |
|---|---|---|
| ENSE00002690836 | 75647371 | 75647974 |
| ENSE00002718880 | 75646251 | 75646786 |
Expression profiles
Bgee: expression breadth ubiquitous, 155 present calls, max score 96.42.
FANTOM5 (CAGE): breadth broad, TPM avg 0.6127 / max 85.2959, expressed in 208 samples.
FANTOM5 promoters (5 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 162762 | 0.2355 | 97 |
| 162760 | 0.1733 | 94 |
| 162764 | 0.1028 | 21 |
| 162761 | 0.0680 | 28 |
| 162763 | 0.0330 | 13 |
Top tissues by expression
234 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| sperm | CL:0000019 | 96.42 | gold quality |
| kidney epithelium | UBERON:0004819 | 91.71 | silver quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 90.65 | gold quality |
| left testis | UBERON:0004533 | 85.46 | gold quality |
| right testis | UBERON:0004534 | 84.50 | gold quality |
| ileal mucosa | UBERON:0000331 | 82.93 | gold quality |
| testis | UBERON:0000473 | 82.55 | gold quality |
| pancreatic ductal cell | CL:0002079 | 82.35 | silver quality |
| mucosa of transverse colon | UBERON:0004991 | 82.27 | gold quality |
| islet of Langerhans | UBERON:0000006 | 82.25 | gold quality |
| right uterine tube | UBERON:0001302 | 82.09 | gold quality |
| adult mammalian kidney | UBERON:0000082 | 81.78 | gold quality |
| gall bladder | UBERON:0002110 | 80.52 | gold quality |
| C1 segment of cervical spinal cord | UBERON:0006469 | 79.69 | gold quality |
| duodenum | UBERON:0002114 | 79.11 | gold quality |
| jejunal mucosa | UBERON:0000399 | 78.44 | gold quality |
| spinal cord | UBERON:0002240 | 77.83 | gold quality |
| bronchial epithelial cell | CL:0002328 | 77.58 | gold quality |
| kidney | UBERON:0002113 | 77.41 | gold quality |
| body of stomach | UBERON:0001161 | 76.69 | gold quality |
| bronchus | UBERON:0002185 | 76.32 | gold quality |
| pancreas | UBERON:0001264 | 76.17 | gold quality |
| rectum | UBERON:0001052 | 75.72 | gold quality |
| epithelial cell of pancreas | CL:0000083 | 75.64 | gold quality |
| metanephros cortex | UBERON:0010533 | 75.31 | gold quality |
| cortex of kidney | UBERON:0001225 | 75.13 | gold quality |
| stomach | UBERON:0000945 | 75.11 | gold quality |
| colonic mucosa | UBERON:0000317 | 75.05 | gold quality |
| right lobe of liver | UBERON:0001114 | 74.28 | gold quality |
| body of pancreas | UBERON:0001150 | 73.99 | gold quality |
Single-cell (SCXA)
Detected in 5 experiment(s), a significant marker in 4.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-MTAB-10283 | yes | 1387.01 |
| E-MTAB-10287 | yes | 25.31 |
| E-GEOD-125970 | yes | 7.12 |
| E-ANND-3 | yes | 4.50 |
| E-HCAD-31 | no | 3.99 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
15 targeting ERLN, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-144-3P | 99.94 | 73.98 | 2698 |
| HSA-MIR-652-5P | 99.91 | 67.49 | 505 |
| HSA-MIR-579-3P | 99.86 | 71.66 | 3628 |
| HSA-MIR-664B-3P | 99.84 | 71.65 | 3590 |
| HSA-MIR-6739-5P | 99.80 | 67.87 | 2806 |
| HSA-MIR-6733-5P | 99.74 | 67.94 | 2759 |
| HSA-MIR-6848-3P | 99.64 | 66.49 | 885 |
| HSA-MIR-3153 | 99.55 | 67.59 | 2337 |
| HSA-MIR-6843-3P | 99.26 | 66.42 | 915 |
| HSA-MIR-3925-5P | 99.21 | 67.90 | 1466 |
| HSA-MIR-589-5P | 98.72 | 66.96 | 927 |
| HSA-MIR-6830-3P | 98.62 | 68.07 | 1760 |
| HSA-MIR-561-5P | 98.25 | 68.13 | 1365 |
| HSA-MIR-1178-5P | 95.83 | 64.12 | 504 |
| HSA-MIR-2861 | 95.24 | 65.47 | 1056 |
Cross-species orthologs
0 orthologs
Protein
Protein identifiers
Endoregulin — P0DI80 (reviewed: P0DI80)
Alternative names: Small integral membrane protein 6
All UniProt accessions (1): P0DI80
UniProt curated annotations — full annotation on UniProt →
Function. Inhibits the activity of the calcium ATPases ATP2A2/SERCA2 and ATP2A3/SERCA3 by decreasing their apparent affinity for Ca(2+).
Subunit / interactions. Homooligomer. Can also form heterooligomers with other sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA) regulators ARLN, PLN, SLN and STRIT1/DWORF. Monomer. Interacts as a monomer with ATP2A2/SERCA2; the interaction results in inhibition of ATP2A2 Ca(2+) affinity.
Subcellular location. Endoplasmic reticulum membrane.
RefSeq proteins (1): NP_001156469* (*=MANE)
Domains & families (InterPro)
UniProt features (2 total): chain 1, transmembrane region 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-P0DI80-F1 | 77.26 | 0.28 |
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 830 (showing top):
GSE45365_NK_CELL_VS_CD8A_DC_MCMV_INFECTION_UP, GSE18804_SPLEEN_MACROPHAGE_VS_COLON_TUMORAL_MACROPHAGE_UP, GOBP_REGULATION_OF_PROTEIN_POLYMERIZATION, GOBP_ACTIN_FILAMENT_BUNDLE_ORGANIZATION, GOBP_RESPIRATORY_GASEOUS_EXCHANGE_BY_RESPIRATORY_SYSTEM, GOBP_MUSCLE_TISSUE_DEVELOPMENT, CHIARADONNA_NEOPLASTIC_TRANSFORMATION_KRAS_DN, GOBP_CIRCULATORY_SYSTEM_PROCESS, YAO_HOXA10_TARGETS_VIA_PROGESTERONE_UP, MODULE_45, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP, GRAESSMANN_RESPONSE_TO_MC_AND_SERUM_DEPRIVATION_UP, GOBP_EXTRACELLULAR_MATRIX_ASSEMBLY, GOBP_MUSCLE_CELL_PROLIFERATION, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS
GO Biological Process (0):
GO Molecular Function (0):
GO Cellular Component (3): endoplasmic reticulum membrane (GO:0005789), endoplasmic reticulum (GO:0005783), membrane (GO:0016020)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| organelle membrane | 1 |
| nuclear outer membrane-endoplasmic reticulum membrane network | 1 |
| endoplasmic reticulum subcompartment | 1 |
| cytoplasm | 1 |
| endomembrane system | 1 |
| intracellular membrane-bounded organelle | 1 |
| cellular anatomical structure | 1 |
Protein interactions and networks
STRING
310 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| ERLN | ARLN | Q8WVX3 | 805 |
| ERLN | STRIT1 | P0DN84 | 729 |
| ERLN | MRLN | P0DMT0 | 714 |
| ERLN | SLN | O00631 | 606 |
| ERLN | TBC1D3K | A0A087X1G2 | 571 |
| ERLN | CDRT15L2 | A8MXV6 | 520 |
| ERLN | TBC1D3H | P0C7X1 | 479 |
| ERLN | TBC1D28 | Q2M2D7 | 447 |
| ERLN | TBC1D3D | A0A087WVF3 | 444 |
| ERLN | SLC35G6 | P0C7Q6 | 430 |
| ERLN | SLC35G3 | Q8N808 | 419 |
| ERLN | CCDC144A | A2RUR9 | 419 |
| ERLN | SMIM5 | Q71RC9 | 418 |
| ERLN | SPDYE4 | A6NLX3 | 404 |
| ERLN | OR3A2 | P47893 | 402 |
IntAct
0 interactions, top by confidence:
ESM2 similar proteins: A0A1B0GQX2, A0A1B0GTB2, A2BUT0, A2C0D2, A6BM34, A7M911, A8W3J7, B0JYB0, B1WS50, B2J4U1, B2Y1W9, B7JV08, B7KFH4, O19926, O29047, O70901, P0C0X9, P0C179, P0DI80, P27387, P29662, P30395, P31591, P58246, Q06GN1, Q06RE7, Q06SD5, Q06SI9, Q110N3, Q1ACL7, Q28053, Q28280, Q28748, Q28757, Q29149, Q32FX5, Q3J1A4, Q3M5W2, Q46H80, Q54YR4
Diamond homologs: P0DI80, Q3U0I6
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
6 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 4 |
| Likely benign | 0 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
186 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 17:75647365:TTCCA:T | acceptor_loss | 0.9900 |
| 17:75647366:TCCA:T | acceptor_loss | 0.9900 |
| 17:75647367:CCA:C | acceptor_loss | 0.9900 |
| 17:75647368:CA:C | acceptor_loss | 0.9900 |
| 17:75647369:AGA:A | acceptor_loss | 0.9900 |
| 17:75646367:CACAG:C | donor_loss | 0.9800 |
| 17:75646368:ACAG:A | donor_loss | 0.9800 |
| 17:75646369:CAGG:C | donor_loss | 0.9800 |
| 17:75646370:AGGTG:A | donor_loss | 0.9800 |
| 17:75646371:GGT:G | donor_loss | 0.9800 |
| 17:75646372:GTGAG:G | donor_loss | 0.9800 |
| 17:75646373:T:A | donor_loss | 0.9800 |
| 17:75646653:A:AG | acceptor_gain | 0.9700 |
| 17:75646654:G:GG | acceptor_gain | 0.9700 |
| 17:75647369:A:AG | acceptor_gain | 0.9700 |
| 17:75647370:G:GG | acceptor_gain | 0.9700 |
| 17:75646654:GTT:G | acceptor_gain | 0.9500 |
| 17:75647370:GATT:G | acceptor_gain | 0.9500 |
| 17:75646782:ATCAG:A | donor_loss | 0.9300 |
| 17:75646783:TCAGG:T | donor_loss | 0.9300 |
| 17:75646784:CAG:C | donor_loss | 0.9300 |
| 17:75646785:AGGT:A | donor_loss | 0.9300 |
| 17:75646786:GGTAA:G | donor_loss | 0.9300 |
| 17:75646787:G:T | donor_loss | 0.9300 |
| 17:75646788:T:A | donor_loss | 0.9300 |
| 17:75647553:TG:T | donor_gain | 0.9200 |
| 17:75647370:GA:G | acceptor_gain | 0.9100 |
| 17:75646653:AGTT:A | acceptor_gain | 0.8900 |
| 17:75646654:GTTG:G | acceptor_gain | 0.8900 |
| 17:75646374:G:GT | donor_loss | 0.8600 |
AlphaMissense
403 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 17:75647509:T:C | F45L | 0.927 |
| 17:75647511:T:A | F45L | 0.927 |
| 17:75647511:T:G | F45L | 0.927 |
| 17:75647424:G:C | W16C | 0.869 |
| 17:75647424:G:T | W16C | 0.869 |
| 17:75647456:T:A | V27E | 0.843 |
| 17:75647443:G:A | G23R | 0.842 |
| 17:75647443:G:C | G23R | 0.842 |
| 17:75647436:G:C | W20C | 0.840 |
| 17:75647436:G:T | W20C | 0.840 |
| 17:75647501:C:A | A42D | 0.823 |
| 17:75647434:T:A | W20R | 0.820 |
| 17:75647434:T:C | W20R | 0.820 |
| 17:75647419:T:C | F15L | 0.817 |
| 17:75647421:C:A | F15L | 0.817 |
| 17:75647421:C:G | F15L | 0.817 |
| 17:75647450:T:C | L25P | 0.806 |
| 17:75647447:G:A | G24D | 0.802 |
| 17:75647446:G:C | G24R | 0.774 |
| 17:75647497:T:C | F41L | 0.774 |
| 17:75647499:T:A | F41L | 0.774 |
| 17:75647499:T:G | F41L | 0.774 |
| 17:75647422:T:A | W16R | 0.772 |
| 17:75647422:T:C | W16R | 0.772 |
| 17:75647483:T:G | L36R | 0.770 |
| 17:75647489:T:G | L38R | 0.769 |
| 17:75647444:G:A | G23E | 0.760 |
| 17:75647512:G:C | G46R | 0.753 |
| 17:75647467:T:C | F31L | 0.746 |
| 17:75647469:C:A | F31L | 0.746 |
dbSNP variants (sampled 300 via entrez): RS1000140249 (17:75646101 C>A), RS1000740986 (17:75644486 G>C), RS1001122212 (17:75645700 G>A), RS1001236558 (17:75645758 A>G), RS1005564698 (17:75646384 G>A,C), RS1005588108 (17:75647106 C>A,G), RS1005900357 (17:75647894 A>T), RS1006012548 (17:75646838 T>A,C), RS1007046490 (17:75646729 C>T), RS1007057708 (17:75646467 C>G,T), RS1007093534 (17:75645730 G>A), RS1007422382 (17:75647244 G>A), RS1008092852 (17:75644381 A>C,G), RS1008540575 (17:75644601 A>G), RS1009965943 (17:75645692 G>A)
Disease associations
OMIM: gene MIM:620531 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
0 associations (top):
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
13 total (human), top 13 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| methyleugenol | increases expression | 1 |
| sodium arsenite | increases expression | 1 |
| abrine | increases expression | 1 |
| Air Pollutants | increases expression, increases abundance | 1 |
| Benzo(a)pyrene | affects methylation | 1 |
| Ethinyl Estradiol | affects expression | 1 |
| Smoke | increases abundance, increases expression | 1 |
| Tobacco Smoke Pollution | decreases expression | 1 |
| Triclosan | increases expression | 1 |
| Valproic Acid | decreases expression | 1 |
| Cyclosporine | increases expression | 1 |
| Aflatoxin B1 | increases methylation | 1 |
| Genistein | affects expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.